ecrin-mdr-crcClinical2016Colorectal cancerColorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2638141Japan8ECRIN MDRCompletedfalsePhase II study of regorafenib with dose adjustment and pharmacokinetic analysis in advanced colorectal cancerInterventions: Start with regorafenib 120mg/day, and escalate the dosage to 160mg/day if compatible with the criteria at day 15 Primary outcome(s): Desease control rate Study Design: Single arm Non-randomized2016-08-152638141JPRN-UMIN000022884